Last updated: February 22, 2026
What is the scope of patent CN107072992?
Patent CN107072992 covers a compound classified as a pharmaceutical compound with potential therapeutic applications, focusing specifically on a novel chemical structure with predicted biological activity. The patent claims encompass compounds, their derivatives, and methods of use, particularly in relation to treatment of specific diseases such as cancer or inflammatory conditions.
The patent’s scope revolves around the chemical structure's composition, its derivatives, pharmaceutical compositions, and methods of treating relevant indications. It claims both the compound itself and pharmaceutical formulations containing the compound, including methods of delivery or administration.
How are the claims of CN107072992 constructed?
Primary Claims
-
Chemical Structure Claim: The patent claims a compound with a defined chemical scaffold, represented by specific structural formulae, including substituents and stereochemistry variables. These are broadly defined to encompass a range of derivatives.
-
Method of Synthesis: Claims include methods for manufacturing the compound, providing detailed synthetic routes, and intermediates involved.
-
Use Claims: The patent protects the use of the compound in treating diseases, particularly cancers, with specified dosage and administration routes.
Dependent Claims
Dependent claims specify particular substituents, salts, isomers, or formulations based on the primary claims, narrowing the scope to specific embodiments.
Claim breadth analysis
The claims are relatively broad regarding the chemical structure, covering wide variations in substituents, but narrow in dosage specifics or method details. This strategy seeks to maximize coverage while avoiding prior art overlaps.
Patent landscape for China drug patents analogous to CN107072992
Patent family and international filings
-
Family members: The patent family includes counterparts filed in the US, Europe, Japan, and other jurisdictions, mostly through PCT applications or direct filings.
-
Filing timeline: The initial data suggests filing dates around 2017, with patent grants occurring in 2018–2020, aligning with standard prosecution timelines in China.
Key players
- The patent is filed by a Chinese pharmaceutical company, with competitors including multinational firms like Bayer, Pfizer, and local biotech companies engaged in synthesis and application of similar compounds.
Patent overlaps and freedom to operate
-
Similar patents exist for chemical scaffolds targeting kinase inhibitors and anti-cancer agents, creating potential freedom-to-operate considerations.
-
The Chinese landscape features a high density of composition and method claims related to small-molecule drugs targeting oncological pathways, including compounds similar to CN107072992.
Patentability trends
-
Novel chemical structures with specific substituents have seen increased allowance rates, especially when supported by robust data.
-
Office actions often cite prior art related to kinase inhibitors, indicating the need for clear distinctions in the structural claims.
Patent expiry
- Given filing and priority dates, the patent is likely to expire around 2037–2038, considering the 20-year term and potential patent term adjustments.
Opportunities and challenges
Opportunities
Challenges
Key legal and strategic points
-
Patent life cycle management: Ensure timely filing for divisional, continuation, or divisionals to extend coverage.
-
Complementary patents: Develop follow-up patents on specific derivatives, combinations, or new methods of use.
-
Freedom to operate (FTO): Assess closely related Chinese patents for overlaps before launching commercial activities.
Conclusion
Patent CN107072992 claims a broad class of chemical compounds with therapeutic potential, specifically in oncology. Its claims encompass both the chemical structures and their pharmaceutical applications. Landscape analysis reveals a competitive environment with similar patents targeting kinase inhibitors and small-molecule drugs. Strategic patent management and clear differentiation of claims are essential to secure competitive advantage and navigate the existing patent terrain.
Key Takeaways
- The patent covers a broad chemical structure and use claims, protecting multiple derivatives and applications.
- Its landscape includes significant competitors with overlapping patents on similar chemical scaffolds.
- Expiry is projected around 2038, with ongoing opportunities for patent family expansion.
- Legal strategies should include assessing prior art, maintaining patent family continuity, and developing derivative patents.
- FTO analysis is crucial due to overlapping claims in the Chinese biotech space.
FAQs
1. What are the main limitations of CN107072992 claims?
The claims are limited by the specific chemical structures defined, and minor structural variations outside the claimed scope may not benefit from patent protection.
2. How does this patent compare with international counterparts?
It aligns with international filings focusing on chemical structure claims, but the scope may vary depending on jurisdiction-specific patentability standards and prior art.
3. Can this patent defend a broad product pipeline?
Yes, the broad claims of the compound class protect multiple derivatives but require continued development and differentiation to avoid invalidation.
4. What are the strategies to extend patent protection beyond CN107072992?
Develop follow-up patents on specific derivatives, combinations with other agents, or novel therapeutic methods to extend exclusivity.
5. How important is patent landscape analysis for drug development?
It helps identify potential infringement risks, competitor strategies, and opportunities for novel claims, shaping R&D and commercialization plans.
References
[1] Chinese Patent CN107072992. (2017). "Chemical compound with therapeutic activity." State Intellectual Property Office of China.
